Zaire Ebola Pseudovirus

Comprehensive Neutralization Assay Solutions for Advancing Zaire ebolavirus Research

Get your pseudovirus

Zaire Ebola Pseudovirus

This Ebola pseudovirus is pseudotyped with the Glycoprotein of the Zaire variant (GenBank: KP096420.1). These pseudoviruses carry a modified genome that expresses a luciferase (or GFP) reporter gene.

QC report example

Zaire Ebola Pseudovirus Advantages

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Characterization of thermal stability

Stable at least 10 month at -80 °C

Support high-throughput screening

See all QC report get a quote

Zaire Ebola Pseudovirus Features

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293T cells

Enable specific detection

Expression of Zaire Ebo-GP on the surface of the pseudovirus

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions.

Lead Time: 1 - 3 week

We provide you with freshly produced pseudoviruses

Get a quote

Zaire Ebola Pseudovirus Applications

Pseudoviruses provide a safe and versatile platform for Zaire ebolavirus research and the development of therapeutic countermeasures. These pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting Zaire ebolavirus

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

get a quote

Zaire Ebolavirus Background

The Zaire ebolavirus, is the most virulent species of the Ebola virus genus and is responsible for the majority of Ebola virus disease (EVD) outbreaks in humans. First identified in 1976 near the Ebola River in what is now the Democratic Republic of the Congo, it causes a severe hemorrhagic fever characterized by sudden onset of fever, fatigue, muscle pain, vomiting, diarrhea, and, in many cases, internal and external bleeding (WHO). The virus is transmitted through direct contact with the blood or bodily fluids of infected individuals or animals, and it has a high case fatality rate, sometimes exceeding 50% (CDC).

Zaire Ebola Pseudovirus in Publications

June 1, 2015

Pseudoparticle Neutralization Assay for Detecting Ebola- Neutralizing Antibodies in Biosafety Level 2 Settings

Read more >

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL

Documentations

Ebola Zaire - CoA

See all CoAs

MSDS

Access MSDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL